News and Announcements
Elixinol Global Limited (ASX: EXL) appoints Non-Executive Director to lead global expansion
- Published April 17, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Highlights
- Elixinol Global Limited (ASX: EXL) has appointed retail specialist and Fellow of the Australian Institute of Company Directors, Mr Greg Ellery as Non-Executive Director.
- Elixinol specialises in the industrial hemp, dietary supplements and emerging medicinal cannabis, all of which are rapidly moving into mainstream consumer adoption.
- Mr Ellery’s appointment will help to establish Elixinol as the leading FCMG company in its sector.
Elixinol Global Limited (ASX: EXL) has appointed retail specialist and Fellow of the Australian Institute of Company Directors, Mr Greg Ellery as Non-Executive Director effective 12 April 2019.
Mr Ellery comes from a successful FMCG background, as CEO of the Asia Pacific region for Asahi Premium Beverages and executive positions held with Spectrum Brands, Polaroid Corporation, Fosters Group and New Balance Athletics.
Mr Ellery will utilise his established background in leading consumer packaged goods both nationally and throughout the US, Japan and Europe, to support the expanding growth of Elixinol. Elixinol specialises in the industrial hemp, dietary supplements and emerging medicinal cannabis, all of which are rapidly moving into mainstream consumer adoption. His appointment will help to establish Elixinol as the leading FCMG company in its sector.
About Elixinol Global (ASX: EXL)
Elixinol Global Limited (ASX: EXL; OTCQX: ELLXF) through its businesses has a global presence in the cannabis industry including hemp-derived CBD dietary supplements, hemp food and wellness products, as well as cultivation and manufacture of medicinal cannabis products.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
